BTTX vs. BLPH, PTEIQ, ADTX, EVFM, SXTC, ACOR, AKAN, BBLG, SCNI, and SBFM
Should you be buying Better Therapeutics stock or one of its competitors? The main competitors of Better Therapeutics include Bellerophon Therapeutics (BLPH), PolarityTE (PTEIQ), Aditxt (ADTX), Evofem Biosciences (EVFM), China SXT Pharmaceuticals (SXTC), Acorda Therapeutics (ACOR), Akanda (AKAN), Bone Biologics (BBLG), Scinai Immunotherapeutics (SCNI), and Sunshine Biopharma (SBFM). These companies are all part of the "medical" sector.
Bellerophon Therapeutics (NASDAQ:BLPH) and Better Therapeutics (NASDAQ:BTTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.
10.6% of Bellerophon Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 5.2% of Bellerophon Therapeutics shares are owned by insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Bellerophon Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Better Therapeutics has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.
In the previous week, Better Therapeutics had 1 more articles in the media than Bellerophon Therapeutics. MarketBeat recorded 2 mentions for Better Therapeutics and 1 mentions for Bellerophon Therapeutics. Bellerophon Therapeutics' average media sentiment score of 0.53 beat Better Therapeutics' score of 0.00 indicating that Better Therapeutics is being referred to more favorably in the news media.
Bellerophon Therapeutics' return on equity of 0.00% beat Better Therapeutics' return on equity.
Bellerophon Therapeutics is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.
Bellerophon Therapeutics currently has a consensus target price of $2.00, suggesting a potential upside of 3,471.43%. Better Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 44,676.12%. Given Bellerophon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Better Therapeutics is more favorable than Bellerophon Therapeutics.
Bellerophon Therapeutics received 314 more outperform votes than Better Therapeutics when rated by MarketBeat users. Likewise, 60.42% of users gave Bellerophon Therapeutics an outperform vote while only 41.67% of users gave Better Therapeutics an outperform vote.
Summary
Better Therapeutics beats Bellerophon Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Better Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Better Therapeutics Competitors List
Related Companies and Tools
